NCT01394016 is a Phase 1 clinical trial of Abemaciclib in Advanced Cancer, sponsored by Eli Lilly and Company.

Who is sponsoring NCT01394016?

NCT01394016 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT01394016?

Interventions in NCT01394016: Abemaciclib, Fulvestrant.

What condition does NCT01394016 study?

NCT01394016 studies Advanced Cancer.

Is NCT01394016 still recruiting?

NCT01394016 is currently completed. Last updated 19 September 2024.

Are results published for NCT01394016?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-09-19 · How we verify

NCT01394016

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

Completed Phase 1 Results posted Last updated 19 September 2024

What this trial tests

Phase 1 trial testing Abemaciclib in Advanced Cancer in 225 participants. Completed in 12 April 2022.

Timeline

7 December 2009

Primary endpoint
29 May 2014

12 April 2022

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	225
Start date	7 December 2009
Primary completion	29 May 2014
Estimated completion	12 April 2022
Sites	3 locations across United States

Drugs / interventions tested

Abemaciclib (abemaciclib) — full drug profile →
Fulvestrant (fulvestrant) — full drug profile →

Conditions studied

Advanced Cancer — all drugs for Advanced Cancer →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

18 and older, any sex, with Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Clinically Significant Effects Primary · Baseline up to 233 weeks

The number of participants with clinically significant findings in the study were reported in this outcome measure.

Group	Value	95% CI
Part A - Cohort 1: 50 mg Abemaciclib - Q24H	0
Part A - Cohort 2: 100 mg Abemaciclib - Q24H	0
Part A - Cohort 3: 150 mg Abemaciclib - Q24H	0
Part A - Cohort 4: 225 mg Abemaciclib - Q24H	0
Part A - Cohort 5: 75 mg Abemaciclib - Q12H	0
Part A - Cohort 6: 100 mg Abemaciclib - Q12H	0
Part A - Cohort 7: 150 mg Abemaciclib - Q12H	0
Part A - Cohort 8: 200 mg Abemaciclib - Q12H	1
Part A - Cohort 9: 275 mg Abemaciclib - Q12H	2
Part B - 150 mg Abemaciclib - Q12H	1
Part B - 200 mg Abemaciclib - Q12H	5
Part C - 150 mg Abemaciclib - Q12H	0

Percentage of Participants With Tumor Response - Overall Response Rate (ORR), Disease Control Rate (DCR) Secondary · Baseline through Study Completion (Up to 285 weeks)

ORR is the percentage of participants who exhibit a confirmed complete response (CR) or partial response (PR) as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. DCR is defined as the percentage of participants in the analysis population who e

ORR

Group	Value	95% CI
Part B - 150 mg Abemaciclib - Q12H	3.8	0.1 – 19.6
Part B - 200 mg Abemaciclib - Q12H	2.4	0.1 – 12.6
Part C - 150 mg Abemaciclib - Q12H	0	NA – NA
Part C - 200 mg Abemaciclib - Q12H	0	NA – NA
Part D - 150 mg Abemaciclib - Q12H	32.0	14.9 – 53.5
Part D - 200 mg Abemaciclib - Q12H	18.2	5.2 – 40.3
Part E - 150 mg Abemaciclib - Q12H	0	NA – NA
Part E - 200 mg Abemaciclib - Q12H	7.7	0.2 – 36.0
Part F - 150 mg Abemaciclib - Q12H	0	NA – NA
Part G - 200 mg Abemaciclib (Q12H) + Fulvestrant (Measurable Disease)	45.5	16.7 – 76.6
Part G - 200 mg Abemaciclib (Q12H) + Fulvestrant (Non-measurable Disease)	0	NA – NA

DCR

Group	Value	95% CI
Part B - 150 mg Abemaciclib - Q12H	42.3	23.4 – 63.1
Part B - 200 mg Abemaciclib - Q12H	52.4	36.4 – 68.0
Part C - 150 mg Abemaciclib - Q12H	0	NA – NA
Part C - 200 mg Abemaciclib - Q12H	20	4.3 – 48.1
Part D - 150 mg Abemaciclib - Q12H	68.0	46.5 – 85.1
Part D - 200 mg Abemaciclib - Q12H	72.7	49.8 – 89.3
Part E - 150 mg Abemaciclib - Q12H	23.1	5.0 – 53.8
Part E - 200 mg Abemaciclib - Q12H	30.8	9.1 – 61.4
Part F - 150 mg Abemaciclib - Q12H	13.3	1.7 – 40.5
Part G - 200 mg Abemaciclib (Q12H) + Fulvestrant (Measurable Disease)	72.7	39.0 – 94.0
Part G - 200 mg Abemaciclib (Q12H) + Fulvestrant (Non-measurable Disease)	87.5	47.3 – 99.7

Pharmacokinetics (PK): Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib Secondary · Day 28 (0, 1, 2, 4, 6, 8, 10, 24 hours post-dose) of Cycle 1

PK: Cmax,ss of Abemaciclib.

Group	Value	95% CI
50 mg Abemaciclib - Q24H	NA	± NA
100 mg Abemaciclib - Q24H	102	± 198
150 mg Abemaciclib - Q24H	189	± 35
225 mg Abemaciclib - Q24H	121	± 38
75 mg Abemaciclib - Q12H	58.7	± 37
100 mg Abemaciclib - Q12H	226	± 51
150 mg Abemaciclib - Q12H	249	± 86
200 mg Abemaciclib - Q12H	298	± 72

PK: Area Under the Steady State Plasma Concentration-time Curve Over 24 Hours (AUC 0-24hr,ss) of Abemaciclib Secondary · Day 28 (0, 1, 2, 4, 6, 8, 10, 24 hours post-dose) of Cycle 1

PK: AUC 0-24hr,ss of Abemaciclib.

Group	Value	95% CI
50 mg Abemaciclib - Q24H	NA	± NA
100 mg Abemaciclib - Q24H	1840	± 172
150 mg Abemaciclib - Q24H	NA	± NA
225 mg Abemaciclib - Q24H	NA	± NA
75 mg Abemaciclib - Q12H	1300	± 49
100 mg Abemaciclib - Q12H	3910	± 53
150 mg Abemaciclib - Q12H	4280	± 94
200 mg Abemaciclib - Q12H	5520	± 70

Part A: Recommended Dose for Phase 2 Studies Secondary · Baseline through Study Completion (Up to 285 weeks)

The recommended dose was determined based on a review of overall toxicity, dose reductions, omissions, and pharmacokinetic information from the study.

Group	Value	95% CI
Part A - Abemaciclib	200

Adverse events — posted to ClinicalTrials.gov

Time frame: Baseline through End of Treatment (Up to 645 weeks). Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Part A - Cohort 1: 50 mg Abemaciclib - Q24H

Serious: 0/4 (0%)

Deaths: 0/4

Part A - Cohort 2: 100 mg Abemaciclib - Q24H

Serious: 1/3 (33%)

Deaths: 0/3

Part A - Cohort 3: 150 mg Abemaciclib - Q24H

Serious: 1/3 (33%)

Deaths: 0/3

Part A - Cohort 4: 225 mg Abemaciclib - Q24H

Serious: 0/3 (0%)

Deaths: 0/3

Part A - Cohort 5: 75 mg Abemaciclib - Q12H

Serious: 1/3 (33%)

Deaths: 0/3

Part A - Cohort 6: 100 mg Abemaciclib - Q12H

Serious: 1/4 (25%)

Deaths: 0/4

Part A - Cohort 7: 150 mg Abemaciclib - Q12H

Serious: 1/3 (33%)

Deaths: 0/3

Part A - Cohort 8: 200 mg Abemaciclib - Q12H

Serious: 1/7 (14%)

Deaths: 0/7

Part A - Cohort 9: 275 mg Abemaciclib - Q12H

Serious: 1/3 (33%)

Deaths: 1/3

Part B - 150 mg Abemaciclib - Q12H

Serious: 7/26 (27%)

Deaths: 3/26

Part B - 200 mg Abemaciclib - Q12H

Serious: 15/42 (36%)

Deaths: 15/42

Part C - 150 mg Abemaciclib - Q12H

Serious: 1/2 (50%)

Deaths: 0/2

Part C - 200 mg Abemaciclib - Q12H

Serious: 3/15 (20%)

Deaths: 7/15

Part D - 150 mg Abemaciclib - Q12H

Serious: 5/25 (20%)

Deaths: 4/25

Part D - 200 mg Abemaciclib - Q12H

Serious: 7/22 (32%)

Deaths: 0/22

Part E - 150 mg Abemaciclib - Q12H

Serious: 5/13 (38%)

Deaths: 1/13

Part E - 200 mg Abemaciclib - Q12H

Serious: 5/13 (38%)

Deaths: 5/13

Part F - 150 mg Abemaciclib - Q12H

Serious: 3/15 (20%)

Deaths: 0/15

Part G - 200 mg Abemaciclib (Q12H) + Fulvestrant

Serious: 4/19 (21%)

Deaths: 2/19

Serious adverse events (70 terms)

Reaction	System	Part A - Cohort 1: 50 mg A…	Part A - Cohort 2: 100 mg …	Part A - Cohort 3: 150 mg …	Part A - Cohort 4: 225 mg …	Part A - Cohort 5: 75 mg A…	Part A - Cohort 6: 100 mg …	Part A - Cohort 7: 150 mg …	Part A - Cohort 8: 200 mg …	Part A - Cohort 9: 275 mg …	Part B - 150 mg Abemacicli…	Part B - 200 mg Abemacicli…	Part C - 150 mg Abemacicli…	Part C - 200 mg Abemacicli…	Part D - 150 mg Abemacicli…	Part D - 200 mg Abemacicli…	Part E - 150 mg Abemacicli…	Part E - 200 mg Abemacicli…	Part F - 150 mg Abemacicli…	Part G - 200 mg Abemacicli…
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Febrile neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Myocardial infarction	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pericardial effusion	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Sinus tachycardia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Colitis	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Duodenitis	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Gastric antral vascular ectasia	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pneumatosis intestinalis	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Rectal haemorrhage	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Small intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chills	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Non-cardiac chest pain	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Abdominal wall abscess	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Abscess	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Cellulitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Other adverse events (521 terms — click to expand)

Reaction	System	Part A - Cohort 1: 50 mg A…	Part A - Cohort 2: 100 mg …	Part A - Cohort 3: 150 mg …	Part A - Cohort 4: 225 mg …	Part A - Cohort 5: 75 mg A…	Part A - Cohort 6: 100 mg …	Part A - Cohort 7: 150 mg …	Part A - Cohort 8: 200 mg …	Part A - Cohort 9: 275 mg …	Part B - 150 mg Abemacicli…	Part B - 200 mg Abemacicli…	Part C - 150 mg Abemacicli…	Part C - 200 mg Abemacicli…	Part D - 150 mg Abemacicli…	Part D - 200 mg Abemacicli…	Part E - 150 mg Abemacicli…	Part E - 200 mg Abemacicli…	Part F - 150 mg Abemacicli…	Part G - 200 mg Abemacicli…
Fatigue	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Sinus tachycardia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hyperglycaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Anxiety	Psychiatric disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Depression	Psychiatric disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Weight decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypoalbuminaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Tumour pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Peripheral sensory neuropathy	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Drug hypersensitivity	Immune system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hyperlipidaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Blood alkaline phosphatase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Blood creatinine increased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypoxia	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Leukopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Seasonal allergy	Immune system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Lymphocyte count decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Aphasia	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Most-reported serious reactions: Anaemia, Pneumonia, Pulmonary embolism, Febrile neutropenia, Neutropenia, Thrombocytopenia, Myocardial infarction, Pericardial effusion.

Data from ClinicalTrials.gov NCT01394016 adverse events section.

Sponsor's own description

The purpose of this study is to determine a safe dose of Abemaciclib to be given to participants with advanced cancer and to determine any side effects that may be associated with Abemaciclib in this population. Efficacy measures will be used to assess the activity of Abemaciclib in this population.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cell cycle proteins as promising targets in cancer therapy.
Otto T, Sicinski P. · · 2017 · cited 1412× · PMID 28127048 · DOI 10.1038/nrc.2016.138
Targeting CDK4 and CDK6: From Discovery to Therapy.
Sherr CJ, Beach D, Shapiro GI. · · 2016 · cited 729× · PMID 26658964 · DOI 10.1158/2159-8290.cd-15-0894
Cyclin D1, cancer progression, and opportunities in cancer treatment.
Qie S, Diehl JA. · · 2016 · cited 527× · PMID 27695879 · DOI 10.1007/s00109-016-1475-3
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, et al · · 2014 · cited 411× · PMID 24919854 · DOI 10.1007/s10637-014-0120-7
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer.
Ye F, Dewanjee S, Li Y, Jha NK, et al · · 2023 · cited 361× · PMID 37415164 · DOI 10.1186/s12943-023-01805-y
CDK4 and CDK6 kinases: From basic science to cancer therapy.
Fassl A, Geng Y, Sicinski P. · · 2022 · cited 351× · PMID 35025636 · DOI 10.1126/science.abc1495
Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.
Tripathy D, Bardia A, Sellers WR. · · 2017 · cited 184× · PMID 28351928 · DOI 10.1158/1078-0432.ccr-16-3157
Cell cycle regulation and anticancer drug discovery.
Bai J, Li Y, Zhang G. · · 2017 · cited 182× · PMID 29372101 · DOI 10.20892/j.issn.2095-3941.2017.0033

Verify or expand the search:

Other trials of Abemaciclib

Trials testing the same drug.

NCT07492641 — BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer · Phase 3 · not yet recruiting
NCT07428018 — Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Onco · Phase 2 · not yet recruiting
NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
NCT06498648 — Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tis · Phase 1, PHASE2 · recruiting
NCT07441369 — Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer · Phase 2 · enrolling by invitation

Other recruiting trials for Advanced Cancer

Currently open trials in the same condition.

NCT07393529 — A Pilot Randomized Controlled Trial of a Social Network Intervention · NA · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07246954 — A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in P · NA · recruiting
NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
NCT07147023 — Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication · NA · active not recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01394016 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01394016.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT01394016

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (70 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of Abemaciclib

Other recruiting trials for Advanced Cancer

Other Eli Lilly and Company trials

Verify against primary sources